, we showed that SR-BI-mediated cholesterol efflux was highly correlated (r 2 ‫؍‬ 0.985) with HDL phosphatidylcholine content. The effects of varying HDL phospholipid composition on SR-BI-mediated free cholesterol flux were not correlated with changes in either the K d or B max values for high affinity binding to SR-BI. We conclude that SR-BI-mediated free cholesterol flux is highly sensitive to HDL phospholipid composition. Thus, factors that regulate cellular SR-BI expression and the local modification of HDL phospholipid composition will have a large impact on reverse cholesterol transport.
The deposition of cholesterol in peripheral cells is opposed by the process of reverse cholesterol transport (RCT) 1 where high density lipoproteins (HDL) remove free cholesterol (FC) from cells and deliver it back to the liver for excretion (1) (2) (3) . The flux of FC between cells and HDL is bi-directional. Depending on the direction of the FC concentration gradient between cells and lipoproteins, either net efflux or net influx of cholesterol can occur (4, 5) . The creation of a cholesterol gradient depends upon many properties of the acceptors and the cell plasma membrane. Such factors include the cholesterol and phospholipid content of the acceptors and plasma membrane (4, 5) , the existence of cholesterol domains within the plasma membrane (6 -10) , and the size, number, and composition of acceptor particles (11) (12) (13) .
Recent studies have shown that, when cells express scavenger receptor BI (SR-BI), the bi-directional flux of FC between cells and HDL is accelerated (8, 14, 15) . The mechanism by which SR-BI mediates FC flux is uncertain. However, recent studies from our laboratory demonstrated that binding of the acceptor particles to SR-BI is not a requirement for SR-BImediated cholesterol efflux (7, 8) . Rather SR-BI induces a reorganization of the plasma membrane cholesterol, and this reorganization is linked to enhanced FC flux (7, 8, 16) . Regardless of the mechanism, evidence is accumulating to support the importance of SR-BI-mediated FC flux in RCT. Recent studies of Ji and colleagues (17) showed that either attenuation or overexpression of hepatic SR-BI in mice led to significantly decreased or increased delivery of HDL FC into bile. In addition, the expression of SR-BI in peripheral cells and in foam cells of the arterial wall suggests a role for SR-BI in the removal of FC from the periphery (15, 18, 19) .
SR-BI-mediated FC flux requires phospholipid in the acceptor (15) , and studies have shown that cholesterol efflux from cells is highly correlated with the concentration of HDL phospholipid in serum (20, 21) . Also, the stimulation of cholesterol efflux upon phospholipid supplementation of serum is closely linked to the levels of SR-BI among cell types (14) . These observations are consistent with epidemiological data demonstrating that humans with low HDL phospholipid levels have a high incidence of coronary artery disease (22) . These findings suggest that changes in HDL phospholipid content may alter SR-BI-mediated FC flux. The current studies explicitly test this hypothesis by determining the effects of manipulating HDL phosphatidylcholine and sphingomyelin content on both the influx and efflux of FC using SR-BI-expressing COS-7 cells. Our results demonstrate that SR-BI-mediated bi-directional FC flux is highly sensitive to HDL phospholipid content and composition.
EXPERIMENTAL PROCEDURES
Materials-Tissue culture plasticware was obtained through Falcon (Lincoln, NJ). Calf serum (CS), bovine serum albumin (BSA), unesterified cholesterol, cholesteryl methyl ether, penicillin, streptomycin, and phospholipase A 2 (PLA 2 , from Crotalus adamanteus venom, P-0790) were purchased from Sigma. [1,2- 3 H]Cholesterol was purchased from PerkinElmer Life Sciences. Bovine brain sphingomyelin, 1,2-dimyristoyl-sn-glycerophosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycerophosphoserine, (POPS), and 1-palmitoyl-2-oleoyl-sn-glycerophosphocholine (POPC) were obtained from Avanti Polar Lipids (Alabaster, AL). All other reagents and organic solvents were purchased from Fisher. The acyl-CoA:cholesterol acyltransferase inhibitor, compound CP113,818, was a generous gift from Pfizer.
Phospholipid Vesicle Preparation and HDL Phospholipid Modification-POPC small unilamellar vesicles (SUV) containing 15 mol % FC were made as described previously (23) . Similar procedures were used to make SUV containing 15 mol % cholesterol and also both POPC and POPS (50% mol/mol). HDL 2 (1.066 g/ml Յ d Յ 1.125 g/ml) and HDL 3 (1.125 g/ml Յ d Յ 1.210 g/ml) were isolated by sequential ultracentrifugation (24). Contaminating LDL was removed from HDL 2 by heparinSepharose column chromatography as described previously (25) . Prior to use, HDL was dialyzed extensively against 0.9% NaCl, 10 mM HEPES (pH 7.4) and sterilized by filtration through a 0.45-m Millipore filter.
To enrich HDL 3 with phospholipid, DMPC, or sphingomyelin, multilamellar vesicles (MLVs) were prepared as described (26) . For enrichment with DMPC, 1-2 mg of HDL 3 protein/ml was incubated for 2 h at 24°C with DMPC MLVs added at doses that ranged from 0.25-to 3-fold the total native amount of HDL 3 phospholipid. For enrichment with sphingomyelin, MLVs were added in amounts ranging from 0.5-to 20-fold the HDL 3 sphingomyelin content (estimated to be 12% of HDL 3 total phospholipid), and the mixture was incubated for 1 h at 37°C. Since the phase transition temperature of sphingomyelin is broad, the mixture was then warmed to 42°C and allowed to slowly cool to 25°C over a 5-h period. During enrichment with either DMPC or sphingomyelin, control HDL 3 was incubated similarly but without adding MLVs. After incubation of the HDL with MLVs, any unreacted MLVs were removed by sequentially filtering the HDL MLV mixture through 0.45-and 0.22-m filters. After overnight storage at 4°C, any remaining MLVs were removed from HDL by centrifugation for 30 min at 3,000 ϫ g. The phospholipid to protein ratio of control HDL 3 used in these studies ranged from 0.27 to 0.48, and the degree of enrichment for the different HDL preparations is indicated under "Results."
Another approach to manipulating the PC content of HDL 3 was PLA 2 treatment. HDL 3 or DMPC-enriched HDL 3 (1-2 mg of protein/ml) in buffer containing 20 mM Tris, 0.15 M NaCl, 8 mM CaCl 2 , and 1% BSA (w/v) was incubated at 37°C from 1.5 to 20 min with 1 g of PLA 2 /ml. The reaction was stopped by the addition of 16 mM EDTA. To remove the enzyme and lyso-PC albumin complexes, the HDL 3 was isolated by ultracentrifugation for 24 h at d ϭ 1.210 g/ml. Control HDL 3 was treated similarly as PLA 2 -treated HDL 3 except without the addition of the enzyme. To remove EDTA, the HDL was dialyzed extensively against 0.15 M NaCl containing 10 mM HEPES.
Cell Culture and Transient Transfections-COS-7 cells were maintained on DMEM supplemented with 10% CS and antibiotics. For transfection, cells were seeded in 100-mm plates and incubated for 18 h at 37°C in DMEM supplemented with 10% CS. Cells were transfected with 10 g of the indicated plasmid and diluted in serum-free DMEM and Fugene 6 (Roche Molecular Biochemicals) as described previously (8) . The plasmid containing mixture was added dropwise to the plated cells. The pSG5 vector (Stratagene, Inc.) with or without murine SR-BI or rat CD36 were prepared using endotoxin-free Qiagen Maxiprep kits (8, 27) .
Measurement of Cholesterol Efflux and Influx-After transfection, the cells were removed from the 100-mm plates by trypsinization. The transfected cells were suspended in 10% CS/DMEM containing 2 g of CP113,818/ml and replated into 12-well plates. One 100-mm plate yielded one 12-well plate. For cholesterol efflux, 1 ml of 10% CS/DMEM containing 6 Ci of [ 3 H]cholesterol/ml and 2 g of CP113,818/ml was added to the transfected cells immediately after replating. After 24 h of incubation with the labeling medium, the cells were washed once with 1% BSA/DMEM and once with DMEM. Medium containing HDL or phospholipid vesicles at the desired concentration was then added to the cells and incubated at 37°C for varying times. At the indicated time points, 150-l aliquots of the medium were taken and filtered through 0. 45 Analytical Procedures-The unesterified and esterified cholesterol contents of HDL and cells were measured by gas-liquid chromatography as described previously (28) . Cell and HDL protein determinations were done using the method of Lowry et al. (29) as modified by Markwell et al. (30) . HDL phospholipid was determined by the method of Sokoloff and Rothblat (31) . The sizes of native and modified HDL samples were determined by gel exclusion chromatography on a 25-ml Superose 6 column (Amersham Pharmacia Biotech). Briefly, 300 g of HDL protein in a volume of 400 l were run at 0.4 ml/min in 10 mM potassium phosphate buffer (pH 7.2), 150 mM NaCl. HDL elution was monitored by absorbance at 280 nm.
Kinetic Analysis-The transfer of FC between cells and HDL has been shown to be a bi-directional process. In the current studies, the kinetic analysis assumes a closed system in which FC exists in one of two pools, either the HDL pool or the cellular pool, and the analysis of flux data was accomplished as described previously (4) . In our experiments, the kinetic analysis of the bi-directional flux of FC is not affected by the esterification of cholesterol, as acyl-CoA:cholesterol acyltransferase was inhibited during all incubations. A single exponential equation that describes the bi-directional transfer between two pools was fitted to the data by computer (Prism, GraphPad Inc., San Diego, CA It should be noted that the estimates of mass flux do not take into account the contribution of SR-BI-mediated selective uptake of HDL cholesteryl ester (16, 27, 32) .
Radioiodination of Native and Modified HDL and Analysis of HDL Binding to SR-BI-Native and modified HDL 3 particles were dialyzed against PBS, 0.25 mM EDTA (pH 7.4), and iodinated with Na 125 I using the modified ICL method as described (33) . The sample was then passed through a PD-10 column equilibrated with PBS, 0.25 mM EDTA (pH 7.4), and dialyzed against PBS, 0.25 mM EDTA, 100 mM KI (pH 7.4), followed by 3 changes of PBS, 0.25 mM EDTA (pH 7.4) at 4°C. The recovery of iodinated particles was 80 -90%. The specific activities for various HDL particles ranged from 146 to 670 cpm/ng of protein.
For binding analysis, COS-7 cells were transfected with SR-BI expression plasmid or vector as described above and replated in 24-well plates. Twenty four hours later, the cells were washed 3 times with HEPES-buffered Eagle's minimal essential medium containing 1% BSA. Native or modified HDL particles were then added in the same medium (0.5 ml) to triplicate wells, and the cells were incubated for 90 min at 37°C. At the end of the incubation, the medium was removed and centrifuged at 10,000 ϫ g for 5 min, and an aliquot was used for ␥-counting to determine the free ligand concentration. Cells were placed on ice and washed three times with cold medium containing 1% BSA and three times with cold PBS (pH 7.4), followed by solubilization in 0.5 ml of 0.1 NaOH at room temperature. The sample was transferred to a vial for ␥-counting after which it was used for protein determination (29) . SR-BI-specific binding of native or modified HDL was determined by subtracting values for vector-transfected cells from SR-BI-expressing cells to generate a SR-BI-vector curve. Binding parameters for B max and K d values were obtained for the SR-BI vector curve by nonlinear regression (Prism, GraphPad Inc., San Diego, CA) using a one-site binding isotherm as indicated (34, 35) . 2 and HDL 3 as FC Acceptors-Since HDL 2 is enriched in phospholipid in comparison to HDL 3 (36) , initial studies compared cholesterol efflux from control or SR-BI-expressing COS-7 cells to the two lipoprotein particles (Fig.  1, A and B) . At all HDL 2 or HDL 3 protein concentrations, FC efflux was 5-to 7-fold greater in SR-BI-expressing cells compared with control cells. When the data were normalized to HDL protein, HDL 2 was more efficient than HDL 3 at stimulating efflux in both SR-BI-expressing ( Fig. 1A ) and control cells (Fig. 1B) . However, this difference was more pronounced in SR-BI-expressing cells than in control cells. When the efflux values were normalized to HDL phospholipid content (Fig. 1 , C and D), there was no difference in efflux efficiency between HDL 2 and HDL 3 in either control or SR-BI-expressing cells. This demonstrates that the difference in efficiency seen with similar protein concentrations is due to HDL 2 being more enriched with phospholipid compared with HDL 3 .
RESULTS

Comparison of HDL
Enrichment of HDL 3 with PC-We tested the role of HDL phospholipid in SR-BI-mediated FC flux by enriching HDL 3 with DMPC. Shown in Fig. 2, A and B , is the time courses of efflux and influx with SR-BI-expressing cells incubated with native HDL 3 or DMPC-enriched HDL 3 . There was substantially more cholesterol efflux with DMPC-enriched HDL compared with native HDL (Fig. 2A) . In contrast, there was no effect of DMPC enrichment on the initial rate of cholesterol influx with SR-BI-expressing cells (Fig. 2B) . For subsequent experiments, rate constants for efflux (k e ) and influx (k i ) were calculated by curve fitting (see "Experimental Procedures") and are presented as k e and k i in fraction/h.
Incubation of control COS-7 cells with HDL 3 (20 g of protein/ml) that had been enriched with increasing levels of DMPC showed a small effect of HDL 3 PC enrichment (slope ϭ 0.0025 Ϯ 0.0001) on efflux (Fig. 3A) . However, there was a 25-fold greater effect of HDL 3 PC enrichment on SR-BI-mediated efflux (slope ϭ 0.0604 Ϯ 0.003). Unlike SR-BI-mediated efflux, there was no effect of HDL 3 PC enrichment on SR-BImediated influx, and similarly, no effect was seen with control cells (Fig. 3B) . Similar results were observed when SR-BIexpressing or control cells were incubated with either HDL 3 or PC-enriched HDL 3 at 200 g of HDL protein/ml (data not shown). Depletion of HDL 3 PC with PLA 2 -We next examined the role of HDL PC in SR-BI-mediated cholesterol flux by decreasing the PC content of HDL 3 with phospholipase A 2 treatment. As shown in Fig. 4A , depletion of HDL 3 PC had a large effect on SR-BI-mediated cholesterol efflux, decreasing the rate constant (k e ) by 70%. Depletion of HDL PC also decreased the rate of cholesterol influx in SR-BI-expressing cells (Fig. 4B) . Unlike SR-BI-expressing cells, depletion of HDL 3 PC resulted in little or no change in the rates of FC efflux and influx in control cells. Similar results were observed when SR-BI-expressing or control cells were incubated with HDL 3 and PC-depleted HDL 3 at 200 g of HDL protein/ml (data not shown). The use of a combination of DMPC enrichment and PLA 2 treatment to obtain HDL 3 with a graded PC content showed that, regardless of the means used to manipulate HDL 3 PC content, a strong relationship (r 2 ϭ 0.985) existed between SR-BI-mediated efflux and HDL 3 PC content (Fig. 5A ). In contrast, there was no relationship (r 2 ϭ 0.0002) between efflux and HDL PC content in control cells (Fig. 5B) . There was also no correlation between SR-BI-mediated FC influx (r 2 ϭ 0.172) and HDL 3 PC content (data not shown).
Enrichment of HDL 3 with Sphingomyelin-We next examined the effect of HDL sphingomyelin on SR-BI-mediated flux. Shown in Fig. 6 , A and B, are k e and k i when SR-BI-expressing or control cells were incubated with HDL 3 that had been enriched with increasing levels of sphingomyelin. In contrast to PC enrichment of HDL 3 (see Figs. 2, 3, and 5), sphingomyelin enrichment had only a small effect on SR-BI-mediated efflux (Fig. 6A) but a large effect on cholesterol influx (Fig. 6B) . Similar to SR-BI cells, there was only a minimal effect of HDL 3 sphingomyelin enrichment on efflux in control cells but the rate of influx decreased. To compare the effects of sphingomyelin enrichment of HDL in control and SR-BI-expressing cells, the dependence of k i on sphingomyelin content was linearized by plotting the log of k i against the HDL phospholipid to protein ratio (Fig. 6C) . When plotted this way, the difference in slopes (Ϫ0.88 versus Ϫ0.44) indicates that influx to SR-BI cells is 2.8 (ϭ10 (0.88 -0.44) ) times more sensitive to HDL sphingomyelin enrichment than influx to control cells. Similar results were observed when SR-BI-expressing or control cells were incubated with control and sphingomyelin-enriched HDL at 200 g of HDL protein/ml (data not shown).
Effect of Phospholipid Enrichment or Depletion on HDL Size-To determine whether enrichment of HDL with PC or sphingomyelin or depletion of PC by phospholipase treatment significantly altered the size of the HDL, native and modified HDL were analyzed by gel exclusion chromatography. None of these treatments significantly altered the chromatographic profile of HDL (data not shown). Scanu and colleagues (37) also reported that severe depletion of HDL PC by phospholipase treatment did not alter HDL size.
Calculations of Net Flux-The initial rate constants for efflux and influx from Figs. 3 and 6 were used to estimate the initial net flux of FC mass from SR-BI-expressing and control cells incubated with PC or sphingomyelin-enriched HDL 3 (Fig.  7, A and B) . Enrichment of HDL 3 with either PC or sphingomyelin led to enhancements in the net efflux of FC mass from SR-BI-expressing cells. In contrast, there were no changes in net flux of FC mass from control cells incubated with PC or sphingomyelin-enriched HDL. The ratio of k e to k i predicts the steady-state distribution of FC between the HDL and cells after long incubation times (Fig. 8, A and B) (4) . These predictions follow the same trends as the estimates of net flux. In SR-BI- expressing cells incubated with native HDL, the FC was minimally redistributed toward the HDL compared with control cells. The shift in FC to HDL in SR-BI-expressing cells was greatly enhanced upon enrichment of HDL 3 with increasing levels of either PC or sphingomyelin. These effects were much less pronounced with control cells. Fig. 9 , A and B, are representative binding curves for 125 I-labeled native HDL 3 and PC-enriched/PLA 2 -depleted HDL 3 (see Fig. 9 legend) to control and SR-BI-expressing cells. SR-BI-specific binding (dashed curves) was similar between native and the modified HDL particles. The K d values (g of HDL protein/ml) were 8.0 Ϯ 1.4 and 9.0 Ϯ 1.9, and the B max values (ng of HDL protein/mg cell protein) were 127 Ϯ 7 and 127 Ϯ 9 for native and modified HDL, respectively. Summarized in Table I Previous studies (7, 8) from our laboratory suggested that binding of acceptor particles to SR-BI was not required for SR-BI-mediated FC efflux. We next determined if this is also the case for SR-BI-mediated FC influx by comparing the bidirectional flux of FC using neutral (POPC) or charged (POPC: POPS) vesicles with SR-BI-expressing and control cells (Table  II) . Vesicles containing 50 mol % POPS have been shown to bind to SR-BI, whereas vesicles composed of only POPC do not bind to SR-BI (38, 39) . Influx of FC from both POPC and POPC:POPS vesicles was stimulated similarly when SR-BIexpressing cells were compared with control cells. This suggests that binding to SR-BI is not a requirement for SR-BImediated influx. In addition, similar to our previous results (8), SR-BI-mediated efflux was stimulated more with POPC vesicles as acceptors compared with POPC:POPS vesicles. Thus, these data indicate that binding of acceptor/donor particles to SR-BI cannot explain the effect of SR-BI on bi-directional FC flux.
Effect of HDL Phospholipid Composition on Binding to SR-BI-We next tested whether differences in binding of the various modified HDLs to SR-BI-expressing cells could account for the changes in SR-BI-mediated FC flux. Shown in
We also examined whether influx was stimulated in cells expressing CD36, another scavenger receptor to which HDL binds with high affinity (27, 40) . Consistent with the conclusion that HDL binding, per se, is not sufficient to enhance influx of HDL FC, the rate constants (fraction/h) for FC influx from HDL were 0.064 Ϯ 0.006, 0.067 Ϯ 0.005, and 0.170 Ϯ for control, CD36-expressing, and SR-BI-expressing cells, respectively. Thus, similar to previous studies on FC efflux (8) , the simple concentration of HDL particles at the cell membrane via tethering to CD36 does not explain the greater influx of FC seen with SR-BI-expressing cells.
DISCUSSION
Recent studies have shown that the bi-directional flux of FC is accelerated in cells expressing SR-BI (8, 15) . The importance of SR-BI-mediated FC flux in RCT is substantiated by studies showing that manipulations in hepatic SR-BI expression result in parallel changes in both removal of HDL FC from plasma and incorporation of HDL FC into bile (17) . In addition, other studies have shown that SR-BI is present in foam cells of atherosclerotic lesions (17, 19) . The current studies demonstrate that SR-BI-mediated FC flux is very sensitive to the PC and sphingomyelin composition of HDL and that HDL phospholipid composition alters the steady-state distribution of cholesterol between SR-BI-expressing cells and HDL (Fig. 7) . 3 with DMPC markedly enhanced SR-BI-mediated cholesterol efflux (Fig. 3) . This stimulation in SR-BI-mediated efflux was not specific to DMPC enrichment since decreasing native HDL 3 PC content by treat- ment with PLA 2 substantially decreased the rate of SR-BImediated efflux (Fig. 4A) . Furthermore, the difference in SR-BI-mediated efflux to HDL 2 and HDL 3 was explained by the phospholipid content of these native HDL particles (Fig. 1, C  and D) . In addition, SR-BI-mediated efflux was correlated with HDL PC content over a wide range of HDL phospholipid to protein ratios (Fig. 5 ). These findings explain prior studies in which cholesterol efflux was closely correlated to HDL phospholipid content, and where the extent of this phospholipid effect was correlated with SR-BI levels (20, 21, 26) .
The Effect of HDL PC and Sphingomyelin Content on SR-BImediated FC Flux-Enrichment of HDL
Unlike the effect of PC enrichment of HDL on SR-BI-mediated cholesterol efflux (Fig. 3) , enrichment with sphingomyelin had only a minor effect on efflux but caused a large decrease in SR-BI-mediated cholesterol influx (Fig. 6) . The finding that sphingomyelin enrichment of HDL resulted in only a minor stimulation of efflux was surprising since our previous studies showed that sphingomyelin enrichment of whole serum stimulates efflux from Fu5AH cells, which are rich in SR-BI (14) . One possible explanation is that in the present investigation, the initial rates of bi-directional flux were determined, whereas our earlier studies measured efflux at a later time that would also reflect the back flux of cholesterol from medium to cells. This back flux would be influenced by the effect of the sphingomyelin enrichment of HDL, which reduces influx. Another possible explanation for this difference is that enrichment of serum promotes the formation of more efficient cholesterol acceptors, as opposed to just the enrichment of HDL 3 alone, as was done in the present investigation.
Both PC and sphingomyelin enrichment of HDL led to substantial enhancements in the estimated net efflux of FC from Fig. 9 and "Experimental Procedures." Each analysis was performed in triplicate, and each sample was analyzed twice on two different batches of transfected COS-7 cells. The phospholipid to protein ratio of sphingomyelin-enriched HDL was 1.08 Ϯ 0.03. The phospholipid to protein ratios of the other HDL preparations are shown in Fig. 5 . SR-BI-expressing cells but had only a small effect on net flux from control cells (Fig. 6 ). Thus, both types of HDL phospholipid manipulations led to similar effects on cell FC mass, but by different mechanisms. Sphingomyelin enrichment of HDL enhanced net efflux by decreasing SR-BI-mediated influx, whereas PC enrichment of HDL increased SR-BI-mediated efflux.
Mechanisms for SR-BI-mediated FC Flux-
The mechanism by which SR-BI stimulates FC flux remains unresolved. It is conceivable that manipulating the lipid composition of HDL could result in changes in the binding of the lipoprotein to SR-BI. Previous studies from this laboratory have shown that SR-BI expression stimulates efflux of cell cholesterol to acceptors that have been reported not to bind to SR-BI (7, 8) . The present studies have extended these observations and also suggest that neither efflux nor influx of cholesterol is a function of specific, high affinity binding of the type that has been shown to promote selective uptake of cholesteryl esters from HDL (27, 34, 41) . Consistent with this conclusion are the following observations. 1) Cholesterol influx studies using both neutral SUV donors, which do not bind to SRBI, and negatively charged vesicles, which do bind, demonstrated similar enhancements of influx upon expression of the receptor (Table II) . (Figs. 3, 6, and 9) .
In contrast to the observations discussed above, one set of modified HDL particles did show a parallel relationship between flux and binding. Thus, HDL severely depleted in PC (i.e. 79% reduction) exhibited reduced influx and efflux (Fig. 4) , together with reduced binding affinity (Table I) . However, the change in binding affinity was minor (2-fold), and the same relative changes in efflux were seen at 200 g/ml HDL protein at which concentration SR-BI would be essentially saturated with bound HDL whether the K d was 6 or 15 g/ml. Thus, the change in binding affinity is unlikely to explain the changes in flux seen with PLA 2 -treated HDL. More likely the changes in FC flux may be related to the extensive removal of PC which would produce an HDL relatively enriched in sphingomyelin that would be expected to exhibit both reduced efflux and influx of FC. In addition, similar to the present results, studies of Lagrost and colleagues (42) showed that FC efflux from SR-BIrich hepatoma cells is decreased when the apolipoprotein AI (apoAI) content of HDL is replaced by apoAII, even though other studies have shown that the binding affinity of these apoAII-enriched particles is higher compared with native HDL (43) . Furthermore, a recent study by Chen et al. (44) demonstrated that an antibody directed against SR-BI which blocks both HDL binding and selective cholesteryl ester uptake does not reduce the efflux of cellular FC to HDL.
In contrast to the studies discussed above, recent studies of Gu and colleagues (45) are consistent with binding of HDL to SR-BI being essential for SR-BI-mediated FC efflux. It was reported that antibody to SR-BI does block FC efflux to HDL and that mutations that block HDL binding to SR-BI also block FC efflux (45) . The basis for these differences is unclear at present, although a number of possibilities may be suggested. For example, PC enrichment of HDL in the present study might create a small subset of particles that bind to SR-BI with higher affinity and are responsible for the enhanced SR-BImediated FC efflux. It seems unlikely to us that a small subset of particles, undetectable by binding analysis, could explain the 25-fold increase in SR-BI-mediated FC efflux, but this possibility cannot be excluded. Another possibility, previously suggested (8, 16) , is that SR-BI-mediated FC efflux has two components, one of which requires HDL binding to SR-BI, whereas the other, which occurs with neutral phospholipid vesicles (8) and cyclodextrin acceptors (7), may reflect changes in plasma membrane lipid domains and be independent of acceptor binding. Although these points are currently unresolved, it is clear from the studies with CD36 that simple binding of HDL to the cell surface is not sufficient to enhance the bi-directional flux of FC between HDL and cells.
The primary mechanism of FC flux with control cells would be aqueous diffusion (46) since COS-7 cells have minimal background levels of SR-BI (27) and ATP binding cassette transporter-1 (ABC-1) (58). Recent studies from our laboratory suggest that SR-BI enhances cholesterol efflux by reorganizing cholesterol domains in the plasma membrane resulting in areas of the membrane having accelerated rates of cholesterol desorption (7, 8) . This conclusion comes from comparative studies on SR-BI-positive and control cells showing that SR-BI expression results in increased sensitivity of plasma membrane cholesterol to cholesterol oxidase and in an increased size of the fast pool of FC available for cyclodextrin-mediated efflux. Presumably, SR-BI reorganization of the membrane also creates domains where FC molecules released from HDL can be readily incorporated into the membrane. Whether these domains of the membrane are the same as the "hydrophobic pathway" (34) or caveolae that are proposed to be involved in SR-BI-mediated selective uptake of cholesteryl ester is unclear at this time (47, 48) .
The stimulation in efflux observed with PC enrichment of HDL is likely due to the excess phospholipid solubilizing the desorbed cholesterol molecules, and the more dramatic effect with SR-BI-expressing cells compared with control cells is a result of the enhanced rate of cholesterol desorption induced by SR-BI expression. Conversely, depletion of HDL PC leads to an insufficient solubilization of the desorbed molecules, thereby limiting the rate of SR-BI-mediated cholesterol efflux. The finding of a shift in FC localization from the core to the surface of PC-depleted HDL might also contribute to the ineffective solubilization of desorbed cholesterol molecules (25) .
The lack of an effect on SR-BI-mediated influx of FC when HDL PC content was manipulated is consistent with studies showing that the desorption rate of FC from model membranes, and thus presumably the surface of HDL particles, is not affected by the PC to cholesterol ratio (46) . The sphingomyelin effect on influx is likely due to a decrease in the rate of FC desorption from the surface of the HDL resulting from the high affinity that sphingomyelin has for cholesterol (49, 50) . This would be consistent with prior studies showing that the rates of desorption from model membranes are decreased when vesicles containing sphingomyelin are compared with those containing PC alone. Physiological Significance-The present studies demonstrate that HDL PC and sphingomyelin content play an important role in determining the rate and direction of net transfer of FC with SR-BI-expressing cells. Phosphatidylcholine is the main phospholipid subclass present in HDL. From the current studies, it is expected that factors which modulate both HDL PC content and SR-BI expression would have profound effects on RCT. There are many studies that support the belief that HDL phospholipid plays a key role in RCT. Previous studies from this laboratory have shown that efflux to serum from hepatoma cells, which naturally express high levels of SR-BI, is correlated better to HDL phospholipid than to other serum parameters (5, 20, 21, 51) . Other studies have shown that patients with coronary artery disease have lower HDL phospholipid levels compared with controls (22) . In addition, patients with type II Alagille syndrome have HDL phospholipid to protein ratios similar to the PC-enriched HDL in the current studies (52) . These particles are much more efficient than control HDL at stimulating efflux, and patients with this disease rarely have coronary heart disease (52).
The lipid composition of HDL differs among subclasses and results from the action of a number of factors. These factors, acting in concert, will serve to regulate the bi-directional flux of FC between SR-BI-expressing cells and HDL in both the peripheral lymph, where the process of RCT is initiated, and in the liver where the final steps of RCT occur (for reviews see Refs. 53 and 54). Among the different factors are those in serum, which include lecithin cholesterol acyltransferase, cholesteryl ester transfer protein, and phospholipid transfer protein, as well as a number of cell-surface lipases such as hepatic triglyceride lipase and lipoprotein lipase. It is also likely that the recently discovered secretory tissue phospholipases, such as the endothelially derived phospholipase (55), phospholipase A 2 (56) , and sphingomyelinase (57) will alter HDL phospholipid and, consequently, influence the mobilization of FC from the periphery. Thus, the present findings suggest that tissue-or cell-localized phospholipase activity may alter net FC flux via SR-BI-mediated mechanisms by changing the phospholipid content of HDL particles in the immediate vicinity of the cell.
